SOURCE: Medpace


July 16, 2012 09:43 ET

Medpace Completes Construction on a New Clinical Pharmacology Unit -- Expanding Phase I-IIA Clinical Research Capabilities

CINCINNATI, OH--(Marketwire - Jul 16, 2012) - Medpace, Inc. today announced the opening of the new Medpace Clinical Pharmacology Unit (CPU). The CPU unit will operate at 5355 Medpace Way, Cincinnati, OH. The existing facility in Norwood will close at the conclusion of the move. The new Medpace CPU is a 60,000 square foot state-of-the-art facility doubling the size of the previous CPU -- increasing Medpace's ability to conduct multiple studies with a total of 96 beds for overnight stays. The facility houses a pharmacy, processing labs, and a dedicated patient recruitment staff for both the recruitment and screening of study subjects. The new CPU joins the Medpace global headquarters and the Medpace Clinical Research Organization (CRO).

"The new CPU facility is designed to conduct best in class Phase I studies -- doubling our current capacity and investing in cutting edge instrumentation and process," said Dr. August Troendle, President, Medpace. "The vision for a state of the art campus began in 2008 with the construction of the existing CRO and global headquarters building. By the end of 2012, we will see the completion of Medpace Reference Laboratories (MRL) and Medpace Bioanalytical Laboratories (MBL) facility at the new location. The CPU and the labs complete the fully integrated campus."


Medpace Clinical Pharmacology Unit (CPU) is dedicated to the conduct of early-phase clinical pharmacology studies in normal healthy volunteers, special populations, and patient populations over a spectrum of diseases. Medpace CPU is a fully owned subsidiary of Medpace, Inc. A new state-of-the-art facility opened in July 2012 on the Medpace clinical research campus which is centrally located in Cincinnati, Ohio, approximately 20 miles from the Greater Cincinnati / Northern Kentucky International Airport.


Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, Medpace has assembled the industry's most experienced and therapeutically focused teams to execute at every level of the company's operations, providing complete and seamless drug development services. 

Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 1200 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, centralized imaging core laboratory management and reading from Imagepace, and medical device development from Medpace Medical Device.

Visit the Medpace website at